ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business

Increased FDA scrutiny after quality lapses weigh on Indian drugmakers

NEW DELHI (NewsRise) -- Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and other Indian drugmakers are reeling under increased scrutiny from the U.S. Food & Drug Administration, after the regulator flagged a series of safety lapses and quality control issues at their local facilities.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more